Medicines and Healthcare products Regulatory Agency

CERTIFICATE NUMBER : UK MIA(IMP) 14076 Insp GMP/GDP/IMP 14076/29642-0029[I]

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER*(1),(2)*

Part 1

Issued following an inspection in accordance with :
Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031)

The competent authority of United Kingdom confirms the following :

The Manufacturer : TAYSIDE PHARMACEUTICALS

Site address : TAYSIDE PHARMACEUTICALS, NINEWELLS HOSPITAL, DUNDEE, DD1 9SY, UNITED KINGDOM

Has been inspected under the national inspection programme in connection with manufacturing authorisation no. UK MIA(IMP) 14076 in accordance with Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031)

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 12/02/2019 , it is considered that it complies with

- The principles and guidelines of Good Manufacturing Practice laid down in Regulation B17 of the Human Medicines Regulations 2012 (as amended)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.

- *(1) Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.*
- *(2) These requirements fulfil the GMP recommendations of WHO.*

Part 2

Human Investigational Medicinal Products

1. MANUFACTURING OPERATIONS

[1.1] Sterile Investigational Medicinal Products

[1.1.1] Aseptically prepared (processing operations for the following dosage forms)

[1.1.1.1] Large volume liquids

[1.1.1.3] Semi-solids

[1.1.1.4] Small volume liquids

[1.1.2] Terminally Sterilised (processing operations for the following dosage forms)

[1.1.2.1] Large volume liquids

[1.1.2.2] Semi-solids

[1.1.2.3] Small volume liquids

[1.1.2.5] Other terminally sterilised prepared products

Sterilisation of single and double wrapped ampoules

[1.2] Non-sterile investigational medicinal products

[1.2.1] Non-Sterile Products (processing operations for the following dosage forms)

[1.2.1.1] Capsules, hard shell

[1.2.1.5] Liquids for external use

[1.2.1.6] Liquids for internal use

[1.2.1.8] Other solid dosage forms

[1.2.1.11] Semi-solids

[1.2.1.12] Suppositories

[1.4] Other products or manufacturing activity

[1.4.2] Sterilisation of active substances/excipients/finished products:

[1.4.2.1] Filtration

[1.4.2.2] Dry heat

[1.4.2.3] Moist heat

[1.5] Packaging

[1.5.1] Primary packaging

[1.5.1.1] Capsules, hard shell

[1.5.1.2] Capsules, soft shell

[1.5.1.5] Liquids for external use

[1.5.1.6] Liquids for internal use

[1.5.1.8] Other solid dosage forms

[1.5.1.11] Semi-solids

[1.5.1.12] Suppositories

[1.5.1.13] Tablets

[1.5.2] Secondary packaging

[1.6] Quality control testing

MHRA-GMDP MHRA

[1.6.1] Microbiological: sterility

[1.6.2] Microbiological: non-sterility

[1.6.3] Chemical/Physical

2. IMPORTATION OF MEDICINAL PRODUCTS

[2.1] Quality control testing of imported medicinal products

[2.1.1] Microbiological: sterility

[2.1.2] Microbiological: non-sterility

[2.1.3] Chemical/Physical

[2.2] Batch certification of imported medicinal products

[2.2.1] Sterile Products

[2.2.1.1] Aseptically prepared

[2.2.1.2] Terminally sterilised

[2.2.2] Non-sterile products

28/03/2019	Name and signature of the authorised person of the Competent Authority of United Kingdom Confidential Medicines and Healthcare products Regulatory Agency Tel : Confidential

MHRA-GMDP MHRA